BACKGROUND: Increasing the dose of renal replacement therapy has been shown to improve survival in critically ill patients with acute kidney injury (AKI) in several smaller European trials. However, a very recent large multicentre trial in the USA could not detect an effect of dose of renal replacement therapy on mortality. Based on those studies, it is not known whether a further increase in dialysis dose above and beyond the currently employed doses would improve survival in patients with AKI. We therefore aimed to assess mortality and renal recovery of patients with AKI receiving either standard (SED) orintensified extended dialysis (IED) therapy in the intensive care unit. METHODS: A prospective randomized parallel group study was conducted in seven intensive care units of a tertiary university hospital. Pre-existing chronic kidney disease was an exclusion criterion. A total of 156 patients (570 screened) with AKI requiring renal replacement therapy were randomly assigned to receive standard dialysis [dosed to maintain plasma urea levels between 120 and 150 mg/dL (20-25 mmol/L)] or intensified dialysis [dosed to maintain plasma urea levels <90 mg/dL (<15 mmol/L)]. Outcome measures were survival at Day 14 (primary) and survival and renal recovery at Day 28 (secondary) after initiation of renal replacement therapy. RESULTS: Treatment intensity differed significantly (P < 0.01 for plasma urea and administered dose). No differences between intensified and standard treatment were seen for survival by Day 14 (70.4% versus 70.7%) or Day 28 (55.6% versus 61.3%), or for renal recovery amongst the survivors by Day 28 (60.0% versus 63.0%). CONCLUSIONS: Although this study cannot deliver a definitive answer, it suggests that increasing the dose of extended dialysis above the currently recommended dose might neither reduce mortality nor improve renal recovery in critically ill patients, mainly septic patients, with AKI.
RCT Entities:
BACKGROUND: Increasing the dose of renal replacement therapy has been shown to improve survival in critically ill patients with acute kidney injury (AKI) in several smaller European trials. However, a very recent large multicentre trial in the USA could not detect an effect of dose of renal replacement therapy on mortality. Based on those studies, it is not known whether a further increase in dialysis dose above and beyond the currently employed doses would improve survival in patients with AKI. We therefore aimed to assess mortality and renal recovery of patients with AKI receiving either standard (SED) or intensified extended dialysis (IED) therapy in the intensive care unit. METHODS: A prospective randomized parallel group study was conducted in seven intensive care units of a tertiary university hospital. Pre-existing chronic kidney disease was an exclusion criterion. A total of 156 patients (570 screened) with AKI requiring renal replacement therapy were randomly assigned to receive standard dialysis [dosed to maintain plasma urea levels between 120 and 150 mg/dL (20-25 mmol/L)] or intensified dialysis [dosed to maintain plasma urea levels <90 mg/dL (<15 mmol/L)]. Outcome measures were survival at Day 14 (primary) and survival and renal recovery at Day 28 (secondary) after initiation of renal replacement therapy. RESULTS: Treatment intensity differed significantly (P < 0.01 for plasma urea and administered dose). No differences between intensified and standard treatment were seen for survival by Day 14 (70.4% versus 70.7%) or Day 28 (55.6% versus 61.3%), or for renal recovery amongst the survivors by Day 28 (60.0% versus 63.0%). CONCLUSIONS: Although this study cannot deliver a definitive answer, it suggests that increasing the dose of extended dialysis above the currently recommended dose might neither reduce mortality nor improve renal recovery in critically ill patients, mainly septic patients, with AKI.
Authors: Josée Bouchard; Etienne Macedo; Sharon Soroko; Glenn M Chertow; Jonathan Himmelfarb; Talat Alp Ikizler; Emil P Paganini; Ravindra L Mehta Journal: Nephrol Dial Transplant Date: 2009-08-13 Impact factor: 5.992
Authors: Antoine G Schneider; Rinaldo Bellomo; Sean M Bagshaw; Neil J Glassford; Serigne Lo; Min Jun; Alan Cass; Martin Gallagher Journal: Intensive Care Med Date: 2013-02-27 Impact factor: 17.440
Authors: Antonio D'Avolio; Debora Pensi; Lorena Baietto; Giovanni Pacini; Giovanni Di Perri; Francesco Giuseppe De Rosa Journal: Drugs Date: 2016-08 Impact factor: 9.546
Authors: Philipp Kümpers; Carsten Hafer; Sascha David; Hartmut Hecker; Alexander Lukasz; Danilo Fliser; Hermann Haller; Jan T Kielstein; Robert Faulhaber-Walter Journal: Intensive Care Med Date: 2009-12-03 Impact factor: 17.440
Authors: Philipp Kümpers; Carsten Hafer; Alexander Lukasz; Ralf Lichtinghagen; Korbinian Brand; Danilo Fliser; Robert Faulhaber-Walter; Jan T Kielstein Journal: Crit Care Date: 2010-02-01 Impact factor: 9.097
Authors: K Reinhart; F M Brunkhorst; H-G Bone; J Bardutzky; C-E Dempfle; H Forst; P Gastmeier; H Gerlach; M Gründling; S John; W Kern; G Kreymann; W Krüger; P Kujath; G Marggraf; J Martin; K Mayer; A Meier-Hellmann; M Oppert; C Putensen; M Quintel; M Ragaller; R Rossaint; H Seifert; C Spies; F Stüber; N Weiler; A Weimann; K Werdan; T Welte Journal: Ger Med Sci Date: 2010-06-28